Brinzolamide Brand Name– Azopt
What is Brinzolamide
Brinzolamide is a carbonic anhydrase inhibitor. It is administered topically to the eye for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.
By lowering IOP, brinzolamide reduces the risk of nerve damage and visual field loss in patients with pathologic elevations of intraocular pressure.
Brinzolamide reduces intraocular pressure to the same extent as dorzolamide but ocular burning appears to be less with brinzolamide.
Brinzolamide is a sulfonamide derivative and should not be administered to patients with sulfonamide hypersensitivity.
Final FDA approval for brinzolamide (Azopt) was granted in April 1998.
Indications
- glaucoma
- ocular hypertension
For the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma
Side Effects
- agranulocytosis
- alopecia
- aplastic anemia
- blepharitis
- blurred vision
- chest pain (unspecified)
- conjunctivitis
- diarrhea
- diplopia
- dizziness
- dysgeusia
- dyspepsia
- dyspnea
- foreign body sensation
- headache
- hepatic necrosis
- hyperemia
- hypertonia
- keratitis
- keratoconjunctivitis
- keratopathy
- lacrimation
- nausea
- ocular irritation
- ocular pain
- ocular pruritus
- pharyngitis
- rhinitis
- Stevens-Johnson syndrome
- toxic epidermal necrolysis
- urticaria
- xerophthalmia
- xerostomia
Monitoring Parameters
- intraocular pressure
Contraindications
- breast-feeding
- children
- closed-angle glaucoma
- contact lenses
- hepatic disease
- pregnancy
- renal disease
- renal impairment
- sulfonamide hypersensitivity
Interactions
There are no drug interactions associated with Brinzolamide products.
